SHARE:  

February 16, 2023

BioPharmGuyNews.png

Purchase Data

Promoted Listings

When sensitivity matters in your cancer research, Sysmex Inostics enables more accurate detection of low-frequency biomarkers from a simple blood draw. 


o Expedite your studies

o Get proactive insight into diagnosis and recurrence

o Get quality data at reduced costs

o Unlock relevant biomarker discoveries

o Enjoy white glove service - we support you through research and CDx journey



Sysmex Inostics is more than a CLIA-certified lab, we are helping our partners transform the future of health! Learn More

BioPharmGuy


Just this week we heard from the following:


  • A past client who wanted to buy additional data and said: “We purchased a list late last year – and are very happy with it.”
  • A longtime website user who just realized we would be a good source of data
  • A client who stated: "Awesome, thank you! That is exactly what we are looking for."


Contact us today if you may be interested in hearing about this excellent data everyone is talking about!


-BPG


Companies Added & Removed

37 companies added, three removed this week.


Best New Name:

Aracari Biosciences


Worst New Name:

Ronawk


Excel file of added/removed companies available on our downloads page.

Industry

MDMA Good?

Remember when dealing ecstasy was grounds for 20 years in prison? My, how far we've come.


These days, industrial scale drug dealers are putting out press releases when they land a big customer. This is some really, really wild stuff when you think about it that way. (Yes, ecstasy is still federally banned in Canada)


Know this - Narcos: Canada is going to be the lamest season ever.


NDMA Bad!

GlaxoSmithKline is in hot water after a report from Bloomberg came out revealing they appear to have had more knowledge of NDMA, a cancer-causing contaminant in Zantac, than they let on. The product was approved back in 1983 and removed from the market in 2020.


The FDA believes the quantity of this compound in the medicine increases over time, especially if the drug is stored in a somewhat warm environment. So if you or someone you know is still working through a stockpile of Zantac, maybe think about tossing it and switching to something new.


Team Roast - TCR2

Look - another one of those team pages where the pictures change when you hover over them. Scroll down to play around and see the management get noticeably happier when you point at them. (Management tends to like attention, so maybe that explains this common design feature.)


But wait - it seems the CMO did not get the memo. Not happy in his hover shot...not one bit. To his credit, he did at least pivot slightly whilst keeping his arms crossed and his face crosser. Better than nothing.


Good Luck With All That

Former biotech CEO/general shyster, Vivek Ramaswamy, has started considering making a run for president. Of the United States.


Gee, other than his almost total lack of name recognition amongst the general public, whatever could possibly stand in his way of getting the Republican nomination? 


Guy must be getting real bored swimming in his piles of IPO money, because this is an unbelievable waste of everyone’s time.


To List or Not To List

Found a company we'd never heard of - XLCare Pharma. Or maybe 'company' is too formal of a term...sometimes it can be hard to tell how serious some businesses really are.


This is a predicament we often face here. So do we add this company to our directory or not?


Pros

-Giant image of a pill on homepage

-"teamwork makes the dream work"


Cons

-Atrocious copy, such as “Our Generic Pharmaceutical operates in the Pharmaceuticals business / industry within the Government market – Goods sector.”

-Person left-hand saluting with a Geocities-style animated flag graphic partially blocking her head


Tipping Point

This company does not produce any of its own products and we do not list distributors/middlemen.


Verdict: NOT LISTED


Must be This Tall to Provide

Nice puff piece from Biospace about a company called Enveda Biosciences. They’re working on nature-derived small molecule therapies. Not the first and won't be the last company with that business model, but the $68M they corralled back in December will certainly help the cause.


However, if you were hoping to work here, based on the accompanying picture of their team at a Salt Lake City retreat, you'd better be between 5’9” and 5’11” to stand a chance. Everyone else can eat it: 

Ronawk

If you're gonna name a company Ronawk you'd better have a good explanation. Here's what they came up with:


"With an interest in healing and knowledge, Dr. Mellott and Ms. Decker decided that a Robin, which alleviates pain, and a Hawk, which has been represented as a messenger, were the symbols that best represented their goals. Hence, the name “Ronawk” was born, and so the company was named."


First - where are these pain-healing robins they speak of?


Second - by their explanation of this being a portmanteau of two animals, shouldn't it be either Robawk or Rohawk? Where did that 'n' in the middle come from?


But let's be real - every single one of these options stinks, so what's the difference. 2/10


Drugs Cost Money

R&D costs are going up and Deloitte has released their annual, industry-flagellating report showing just how expensive it is for the 20 biggest drug companies to get a product approved. This year's answer: Eleven billionty dollars.


No, the number they actually pulled out is $2.28B, which sounds really high. But again, these are the 20 largest and undoubtedly some of the least capital-efficient biotech companies.


The report is hard to follow at times, but there are many charts and stuff to convince you to ignore the vagueness of the methodological explanations.


Long story short - small biotech companies don't hire Deloitte, big ones do. So, this type of report should be viewed as being biased towards making the big pharma/biotech companies look great. By throwing numbers like $2.28B per product out there, it helps pharma client companies in their PR push to broadcast the incredible amounts they are spending on R&D.


Does the pharma industry spend a lot on R&D? Absolutely they do. More than almost any industry, in fact. But reports like this come across as having an agenda, so the numbers should always be strongly questioned.

Health & Science

No Think in the Clink

He Jiankui, the Chinese scientist who caused chaos by gene-editing actual human fetuses now agrees he acted too quickly. But when asked if he is sorry for what he did, he said he would need more time to think about that.


He was far too busy for his three years in prison to allow enough reflection time on that. Perhaps he was working fiendishly on creating the finest toilet wine. Or possibly toilet snake wine?


Don't click that link unless you really want to learn about snake wine. And people doing shots of snake blood.

Promote Your Listing at BioPharmGuy

Check your website's analytics - BioPharmGuy is likely your top referrer.


Bump up those referrals even more with a Premium Listing. Learn more - Promoted Listings.

Subscribe!

If you are reading this and are not a subscriber, please join our mailing list.


BioPharmGuy is a registered trademark of Wilsonian LLC, Content © 2023 Wilsonian LLC